Structure via PubChem · Public domain (PubChem)
lusutrombopag
Sign in to saveLusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured in Philadelphia, PA and marketed in Japan by Shionogi. It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.
Chemical data
- Formula
- C29H32Cl2N2O5S
- Molecular weight
- 591.5 g/mol
- IUPAC name
- (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
- SMILES
- CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl
- InChIKey
- NOZIJMHMKORZBA-KJCUYJGMSA-N
- XLogP
- 7.7
- Polar surface area
- 126 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2018
- Admin. routes
- oral
- Indications
- autoimmune thrombocytopenic purpura, Thrombocytopenia, hemorrhage
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 590.141
- Has use
- medication
Show 4 more facts
- canonical SMILES
- CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl
- isomeric SMILES
- CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl
- chemical formula
- C₂₉H₃₂Cl₂N₂O₅S
- medical condition treated
- thrombocytopenia
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured in Philadelphia, PA and marketed in Japan by Shionogi. It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.
It was approved for medical use in the European Union in February 2019.
Excerpted from Wikipedia’s “lusutrombopag” article, available under the CC BY-SA 4.0 licence.